Takeda and Innovent Biologics forge global partnership to advance oncology medicines for solid tumors
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment
Pantoprazole sodium is a proton pump inhibitor reduces stomach acid
Subscribe To Our Newsletter & Stay Updated